Literature DB >> 11738121

Viral load as a primary outcome in human immunodeficiency virus trials: a review of statistical analysis methods.

V Journot1, G Chêne, P Joly, M Savès, H Jacqmin-Gadda, J M Molina, R Salamon.   

Abstract

In Human Immunodeficiency Virus infection, several statistical methods are available to analyze viral load (HIV-1 RNA) used as a surrogate outcome in trials of antiretroviral treatments. We compared the most frequently used methods and applied them to one of these trials, where HIV-1 RNA was measured using two lower limits of detection. Methods were reviewed for different properties dealing with validity, interpretation, and handling. Compared to change of HIV-1 RNA at the end of follow-up or HIV-1 RNA area-under-the-curve during follow-up minus baseline, the most attractive methods appeared to be HIV-1 RNA undetectability, HIV-1 RNA reduction at the end of follow-up with censoring adjustment, and mixed linear model on HIV-1 RNA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11738121     DOI: 10.1016/s0197-2456(01)00158-1

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  9 in total

Review 1.  Basic statistical considerations in virological experiments.

Authors:  Barbra A Richardson; Julie Overbaugh
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

2.  An Evaluation of Statistical Methods for Analyzing Follow-Up Gaussian Laboratory Data with a Lower Quantification Limit.

Authors:  John M Karon; Ryan E Wiegand; Janneke H van de Wijgert; Peter H Kilmarx
Journal:  J Biopharm Stat       Date:  2015       Impact factor: 1.051

3.  Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial.

Authors:  Frederick L Altice; Duncan Smith-Rohrberg Maru; R Douglas Bruce; Sandra A Springer; Gerald H Friedland
Journal:  Clin Infect Dis       Date:  2007-08-13       Impact factor: 9.079

4.  Evaluating the Effect of Early Versus Late ARV Regimen Change if Failure on an Initial Regimen: Results From the AIDS Clinical Trials Group Study A5095.

Authors:  Li Li; Joseph J Eron; Heather Ribaudo; Roy M Gulick; Brent A Johnson
Journal:  J Am Stat Assoc       Date:  2012-07-24       Impact factor: 5.033

5.  Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies.

Authors:  Nancy L Haigwood; David C Montefiori; William F Sutton; Janela McClure; Andrew J Watson; Gerald Voss; Vanessa M Hirsch; Barbra A Richardson; Norman L Letvin; Shiu-Lok Hu; Philip R Johnson
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

6.  Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge.

Authors:  Christiana N Fogg; Jeffrey L Americo; Patricia L Earl; Wolfgang Resch; Lydia Aldaz-Carroll; Roselyn J Eisenberg; Gary H Cohen; Bernard Moss
Journal:  J Virol       Date:  2008-06-04       Impact factor: 5.103

7.  Persistence of virological benefits following directly administered antiretroviral therapy among drug users: results from a randomized controlled trial.

Authors:  Duncan Smith-Rohrberg Maru; Robert Douglas Bruce; Mary Walton; Sandra A Springer; Frederick L Altice
Journal:  J Acquir Immune Defic Syndr       Date:  2009-02-01       Impact factor: 3.731

8.  Cumulative viral load and virologic decay patterns after antiretroviral therapy in HIV-infected subjects influence CD4 recovery and AIDS.

Authors:  Vincent C Marconi; Greg Grandits; Jason F Okulicz; Glenn Wortmann; Anuradha Ganesan; Nancy Crum-Cianflone; Michael Polis; Michael Landrum; Matthew J Dolan; Sunil K Ahuja; Brian Agan; Hemant Kulkarni
Journal:  PLoS One       Date:  2011-05-20       Impact factor: 3.240

9.  Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges.

Authors:  Christiana N Fogg; Jeffrey L Americo; Shlomo Lustig; John W Huggins; Scott K Smith; Inger Damon; Wolfgang Resch; Patricia L Earl; Dennis M Klinman; Bernard Moss
Journal:  Vaccine       Date:  2007-01-03       Impact factor: 3.641

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.